Therapeutic drug monitoring guided dosing versus standard dosing of alectinib in advanced alk positive non-small cell lung cancer patients: study protocol for an international, multicenter phase iv randomized controlled trial (adapt alec)

HIGHLIGHTS

• who: Marinda Meertens and collaborators from the Clu0131u00b4nica Mi Tres Torres, Spain Integrated University Hospital Verona, Italy have published the Article: Therapeutic drug monitoring guided dosing versus standard dosing of alectinib in advanced ALK positive non-small cell lung cancer patients: Study protocol for an international, multicenter phase IV randomized controlled trial (ADAPT ALEC), in the Journal: (JOURNAL) of March/23,/2022
• what: The aim of this RCT is to investigate the effect of TDM-guided dosing of alectinib on treatment outcomes of patients with ALK+ NSCLC. The aim will be to demonstrate, among patients . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.